by Ellen Troyer, MT MA CEO & Chief Research Officer, Biosyntrx Just as hair turns gray with age, bladders weaken and memories lapse, our eyes, too, undergo a metamorphosis. Although these changes are all part of normal aging, some set the stage for more serious eye problems. As eyes age, eyelid muscles weaken, and skin becomes
read more »

It was reported here in November 2017 that two “anti-Ang2” drugs are being studied as potential combination therapies with established anti-VEGF treatments. RG7716 is being tested in combination with Lucentis (Genentech), and nesvacumab (REGN910) is being tested in combination with Eylea (Regeneron). Genentech has now reported that its Phase 2 BOULEVARD trials with RG7716 have
read more »

February is Age-Related Macular Degeneration Awareness Month, and Valentine’s Day is right in the middle. If you would like to send a unique valentine that expresses your love while serving a valuable purpose, read on. Please take this opportunity to teach others about macular degeneration and the need for early diagnosis. This is especially important information for
read more »

by Dan Roberts Advancements in lighting technology for the visually impaired have made big strides during the past 12 years. Before 2005, companies were touting their new full spectrum (“daylight”) lamps as “healthy for aging eyes”. Patients, and even their doctors, were led to believe that the sun at high noon is the best and
read more »

(Updated 4/17/18) Pixium Vision has announced its first successful human implantation of a wireless sub-retinal implant in a patient with atrophic dry age-related macular degeneration (AMD). So far, three patients have been implanted with the device, and results are promising. As reported here in October 2017, the implant, called PRIMA, acts like a tiny solar
read more »

Cases of Glaucoma, the “Sneak Thief of Sight,” Projected to Increase Significantly in Near Future As the population of the United States ages, the number of age-related eye disease cases is projected to grow.  Glaucoma, one of the most common eye diseases, currently affects nearly 3 million people ages 40 and older, according to the
read more »

A global coalition of patients and representative groups concerned with vision health, aging, and avoidable blindness has launched a central hub designed to bring the most up-to-date information on the various forms of Age-related Macular Degeneration (AMD) to patients, their representatives, health care providers, and policy makers. . The Toolkit, available at www.RETINA-AMD.org, was developed
read more »

Apellis Pharmaceuticals has announced that it has finalized the trial design for its planned Phase 3 program evaluating APL-2 for the treatment of patients with geographic atrophy (GA), aka dry macular degeneration. The Phase 3 program, planned to begin in the second half of 2018, will consist of two identical studies to assess the efficacy
read more »

The U.S. Food and Drug Administration (FDA) has approved Luxturna (voretigene neparvovec-rzyl), a new gene therapy developed by Spark Therapeutics, to treat an inherited form of vision loss that can result in blindness.  The most prevalent inherited retinal dystrophies are retinitis pigmentosa (RP), Leber congenital amaurosis (LCA) and Stargardt disease (SD), all of which have
read more »

Please share this article with your ophthalmologist Vision rehabilitation is the standard of care for patients who are losing their vision, and ophthalmologists are key to improving access to care for these patients. Recognizing this, Lighthouse Guild is offering ophthalmologists free access to an eLearning program titled, “Introduction to Vision Rehabilitation.” Dr. Alan R. Morse,
read more »